Aeglea Biotherapeutics, Inc. (AGLE)

NASDAQ: AGLE · IEX Real-Time Price · USD
1.24
+0.03 (2.48%)
Nov 25, 2022 1:00 PM EDT - Market closed
2.48%
Market Cap 78.76M
Revenue (ttm) 5.81M
Net Income (ttm) -85.44M
Shares Out 94.20M
EPS (ttm) -1.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 211,961
Open 1.16
Previous Close 1.21
Day's Range 1.16 - 1.31
52-Week Range 0.37 - 6.86
Beta 1.91
Analysts Buy
Price Target 3.83 (+208.9%)
Earnings Date Nov 3, 2022

About AGLE

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, ... [Read more]

Industry Biotechnology
IPO Date Apr 7, 2016
Employees 69
Stock Exchange NASDAQ
Ticker Symbol AGLE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for AGLE stock is "Buy." The 12-month stock price forecast is 3.83, which is an increase of 208.87% from the latest price.

Price Target
$3.83
(208.87% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer

AUSTIN, Texas , Nov. 15, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative s...

1 week ago - PRNewsWire

Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates

Aeglea (AGLE) delivered earnings and revenue surprises of 20.83% and 72.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates

Interim Clinical Data from Phase 1/2 Trial of Pegtarviliase Expected in Fourth Quarter of 2022; Currently Dosing Cohort 3 at 1.35 mg/kg MAA for Pegzilarginase for the Treatment of Arginase 1 Deficiency ...

3 weeks ago - PRNewsWire

Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential R...

Event to be Held Thursday, October 27 th at 10 AM ET AUSTIN, Texas , Oct. 19, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new ge...

1 month ago - PRNewsWire

Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program

AUSTIN, Texas , Oct. 4, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...

1 month ago - PRNewsWire

Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) An...

AUSTIN, Texas , Aug. 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peop...

2 months ago - PRNewsWire

Paltalk And 3 Other Stocks Under $3 Insiders Are Aggressively Buying

The Dow Jones tumbled by over 500 points on Friday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: PALTASTCOPFI
2 months ago - Benzinga

Aeglea (AGLE) Down on Corporate Restructuring, CEO Steps Down

Aeglea (AGLE) announces a corporate restructuring plan to prioritize the development of AGLE-177 for patients living with homocystinuria. The company's current CEO resigns.

3 months ago - Zacks Investment Research

Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring

Prioritizing  Resources and Focus on AGLE-177 and the Completion of the Ongoing Phase 1/2 Trial in Homocystinuria with Interim Clinical Data Expected in Q4 of 2022 Dr. Anthony Quinn, President, CEO and ...

3 months ago - PRNewsWire

Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment

Aeglea BioTherapeutics (AGLE) seeks a nod for its lead candidate, pegzilarginase, for treating ARG1-D in the European Union. Stock surges post announcement.

3 months ago - Zacks Investment Research

Aeglea BioTherapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Pegz...

AUSTIN, Texas , Aug. 18, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peopl...

3 months ago - PRNewsWire

Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Lags Revenue Estimates

Aeglea (AGLE) delivered earnings and revenue surprises of -3.85% and 55.99%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates

Cohort 2 Completed in Phase 1/2 Trial of AGLE-177; Data Expected in Fourth Quarter of 2022 Actively Engaged with FDA to Identify Potential Paths Forward for Pegzilarginase Gross Proceeds of $45 Million ...

3 months ago - PRNewsWire

Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug

Aeglea (AGLE) gets a Refusal to File letter from the FDA related to the biologics license application for pegzilarginase to treat arginase 1 deficiency. Stock down.

5 months ago - Zacks Investment Research

Aeglea BioTherapeutics Shares Plummet Following Refusal To File Letter From FDA

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) announced the U.S. Food and Drug Administration (FDA) has refused to accept the company's Biologics License Application (BLA) with a Refusal to File (RTF) let...

5 months ago - Benzinga

Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 De...

AUSTIN, Texas , June 2, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peopl...

5 months ago - PRNewsWire

Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market

AUSTIN, Texas , May 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solu...

6 months ago - PRNewsWire

Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Lags Revenue Estimates

Aeglea (AGLE) delivered earnings and revenue surprises of -5.71% and 6.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates

Pegzilarginase BLA submitted to the FDA; if approved, pegzilarginase would be the first FDA-approved treatment for Arginase 1 Deficiency Additional PEACE data supporting potential efficacy of pegzilargi...

6 months ago - PRNewsWire

Aeglea (AGLE) Submits BLA for a Rare Disease Drug to the FDA

Aeglea (AGLE) files a biologics license application to the FDA for pegzilarginase to treat arginase 1 deficiency. The company has requested the FDA to grant priority review to the BLA.

7 months ago - Zacks Investment Research

Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

BLA submission provides FDA with all pegzilarginase program data to review in detail; Aeglea looks forward to working collaboratively with the FDA on next steps in the review process If approved, pegzil...

7 months ago - PRNewsWire

Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Argin...

AUSTIN, Texas , April 11, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peop...

7 months ago - PRNewsWire

Aeglea BioTherapeutics to Participate in the Needham Virtual Healthcare Conferences in April 2022

AUSTIN, Texas , April 6, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peopl...

7 months ago - PRNewsWire

Aeglea BioTherapeutics Announces Presentation of Additional Data from PEACE Phase 3 Study of Pegzilarginase for the T...

AUSTIN, Texas , March 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peop...

7 months ago - PRNewsWire

Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Tops Revenue Estimates

Aeglea (AGLE) delivered earnings and revenue surprises of 3.12% and 18.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research